Marsh & McLennan: Maintaining My 'Buy' Recommendation Following Q2 Earnings

Marsh & McLennan Companies, Inc. remains a compelling long-term growth play despite recent underperformance and cyclical headwinds in the insurance sector. Q2 2026 saw resilient 6% revenue growth, driven mainly by organic initiatives, but margin pressure from rising expenses and a soft P&C pricing cycle.

MRSH stock’s valuation at 20x forward earnings is below its five-year average, supporting a maintained 'buy' rating as cyclical weakness overshadows solid fundamentals. Capital returns favor share buybacks over dividends, with a 2.3% yield and ongoing deleveraging post-McGriff acquisition, positioning MRSH for future flexibility.